Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Capecitabine in Resistant Metastatic Colorectal Cancer
NCT01472770Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Oct 2011
- Primary completion
- May 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, capecitabine in metastatic colorectal cancer (mCRC), sponsored by Vejle Hospital. Started Oct 2011; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01472770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01472770.